A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
Public ClinicalTrials.gov record NCT05418673. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants With Parkinson's Disease and Pathogenic LRRK2 Variants
Study identification
- NCT ID
- NCT05418673
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Biogen
- Industry
- Enrollment
- 7 participants
Conditions and interventions
Conditions
Interventions
- BIIB122 Drug
- BIIB122-Matching Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 30 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 25, 2022
- Primary completion
- Jul 26, 2023
- Completion
- Jul 26, 2023
- Last update posted
- Jun 25, 2024
2022 – 2023
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco (UCSF) | San Francisco | California | 94143 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Rocky Mountain Movement Disorders Center, PC | Englewood | Colorado | 80113 | — |
| Parkinson's Disease and Movement Disorders Center | Boca Raton | Florida | 33486 | — |
| USF Health Byrd Institute | Tampa | Florida | 33613 | — |
| University of Kansas Medical Center Research Institute, Inc. | Kansas City | Kansas | 66160 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Mount Sinai Beth Israel | New York | New York | 10003 | — |
| Weill Medical College of Cornell University | New York | New York | 10021 | — |
| Pennsylvania Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Evergreen Hospital Medical Center | Kirkland | Washington | 98034 | — |
| Inland Northwest Research | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05418673, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2024 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05418673 live on ClinicalTrials.gov.